Last synced on 23 May 2025 at 11:06 pm

Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer

Page Type
Product Code
Definition
A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result is indicated for use only as a prognostic marker by physicians along with a number of other factors to assess the risk of recurrence of breast cancer.
Physical State
RNA isolation kits, enzymes, fluorescent dyes, hybridization systems, computer
Technical Method
Uses Gene expression and computer algorithm that gives risk of recurrence. Gene expression involves isolation of RNA from frozen tumor tissue sections, amplification of RNA and hybridization.
Target Area
breast tumor tissue sections
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6040
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 866.6040 Gene expression profiling test system for breast cancer prognosis

§ 866.6040 Gene expression profiling test system for breast cancer prognosis.

(a) Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.

[72 FR 26291, May 9, 2007]

Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer

Page Type
Product Code
Definition
A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result is indicated for use only as a prognostic marker by physicians along with a number of other factors to assess the risk of recurrence of breast cancer.
Physical State
RNA isolation kits, enzymes, fluorescent dyes, hybridization systems, computer
Technical Method
Uses Gene expression and computer algorithm that gives risk of recurrence. Gene expression involves isolation of RNA from frozen tumor tissue sections, amplification of RNA and hybridization.
Target Area
breast tumor tissue sections
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.6040
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 866.6040 Gene expression profiling test system for breast cancer prognosis

§ 866.6040 Gene expression profiling test system for breast cancer prognosis.

(a) Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.

[72 FR 26291, May 9, 2007]